Advanced Pancreatic Cancer Clinical Trial
Official title:
A Phase I Trial of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, for Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
The study is a first-in-human, Phase I study to assess the safety of ProAgio in participants with advanced solid tumor malignancies including pancreatic cancer.
Pancreatic cancer is the third leading cause of death from cancer in the United States. The median overall survival for patients with metastatic disease who are receiving the most effective combination of chemotherapy regimens remains less than 1 year. ProAgio has been evaluated in nonclinical pharmacology, safety pharmacology, pharmacokinetic (PK), and toxicity studies. It has demonstrated efficacy at treating pancreatic cancer and prolonging survival in mice. ProAgio is being developed for intravenous (IV) administration. All participants will receive ProAgio until disease progression, unacceptable toxicity, or withdrawal from study. Subjects in the dose escalation cohorts who will be administered ProAgio at doses ranging from 3.2 to 36.8 mg/kg. Following the dose escalation phase, an expansion cohort of patients with advanced nonendocrine pancreatic adenocarcinoma will be administered ProAgio at the maximum tolerated dose (MTD) from the dose escalation phase. The expansion cohort will comprise 16 subjects, divided into two blocks (n=8 each) of patients who agree to have optional pre and post-treatment biopsies, and those who decline the optional biopsies. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT03662035 -
Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT06111274 -
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04137536 -
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT04617067 -
Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04469556 -
Pancreatic Adenocarcinoma Signature Stratification for Treatment
|
Phase 2 | |
Recruiting |
NCT04104672 -
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT05100329 -
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02101580 -
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06329947 -
A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
|
Phase 2 | |
Recruiting |
NCT02135822 -
Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04803851 -
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03415802 -
Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT05162118 -
Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04643405 -
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03889795 -
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
|
Phase 1 | |
Completed |
NCT01303172 -
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06422156 -
SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04931381 -
Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT04482257 -
Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.
|
Phase 1 |